Randomized, prospective trial of two schedules of sorafenib 800 mg daily and interferon alpha in metastatic renal cell carcinoma MRCC a GOIRC phase II study.
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2013
At a glance
- Drugs Interferon alpha (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RAPSODY
- 05 Apr 2013 Status changed from not stated to completed.
- 23 May 2011 Last checked against European Clinical Trials record.
- 05 Nov 2010 New trial record.